Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4240482 | 0.99 | KDM4E (0.42) | KDM4ECYP2C19NPC1CYP1A2CYP3A4 | |
| SCHEMBL4245893 | 0.93 | MET (0.41) | KDM4ECYP2C19LMNAROCK1AURKA | |
| Hydrochloric Acid SCHEMBL4243243 | 0.92 | MET (0.40) | KDM4ECYP2C19LMNAROCK1AURKA | |
| SCHEMBL4244704 | 0.91 | KDM4E (0.47) | KDM4ECYP2C19NPC1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4242334 | 0.90 | KDM4E (0.47) | KDM4ECYP2C19NPC1CYP1A2CYP3A4 | |
| SCHEMBL4240352 | 0.87 | CAPN1 (0.39) | KDM4EROCK1ROCK2METKDR | |
| SCHEMBL4247704 | 0.86 | HTR3A (0.38) | ROCK1KMT2ANTSR1NCF1 | |
| SCHEMBL4244710 | 0.86 | NTSR1 (0.39) | SMN1; SMN2KDRKMT2ANTSR1MAPT | |
| SCHEMBL4242997 | 0.86 | MALT1 (0.37) | CYP1A2CYP3A4RAB9ASMN1; SMN2ROCK1 | |
| SCHEMBL4239873 | 0.85 | KMT2A (0.47) | KDM4ECYP2C19NPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531663-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-12 | — | — | US | claimed |
| US-20050026989-A1 | 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-7531663-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-7531663-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-7531663-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20050026989-A1 | 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004007480-A1 | 3-GUANIDINOCARBONYL-1-HETEROARYL-INDOLE DERIVATIVES, PREPARATION PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026989-A1 | 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | IDO1, IDO2, HTR3C | KDM4E 1286/4885CYP2C19 53/4885NPC1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.